

# Shinichirio Ueda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7398949/publications.pdf>

Version: 2024-02-01

21  
papers

344  
citations

933447  
10  
h-index

940533  
16  
g-index

21  
all docs

21  
docs citations

21  
times ranked

601  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study. Hypertension Research, 2022, 45, 106-115.   | 2.7 | 10        |
| 2  | Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyses from the REASON Trial. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 685-694.  | 2.4 | 0         |
| 3  | Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial. RMD Open, 2022, 8, e002226.  | 3.8 | 6         |
| 4  | Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized) Trial. Journal of Clinical Medicine, 2020, 9, 93.      | 2.4 | 2         |
| 5  | Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 2020, 11, 575557.   | 3.5 | 7         |
| 6  | Endosonographic finding of the simultaneous depiction of bile and pancreatic ducts can predict difficult biliary cannulation on endoscopic retrograde cholangiopancreatography. PLoS ONE, 2020, 15, e0235757.   | 2.5 | 1         |
| 7  | Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovascular Diabetology, 2020, 19, 89.           | 6.8 | 20        |
| 8  | Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. PLoS Medicine, 2020, 17, e1003095.  | 8.4 | 57        |
| 9  | Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. Journal of Atherosclerosis and Thrombosis, 2020, 29, .                              | 2.0 | 4         |
| 10 | Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4993-5001.   | 2.4 | 5         |
| 11 | Title is missing!. , 2020, 15, e0235757.  |     | 0         |
| 12 | Title is missing!. , 2020, 15, e0235757.  |     | 0         |
| 13 | Title is missing!. , 2020, 15, e0235757.  |     | 0         |
| 14 | Title is missing!. , 2020, 15, e0235757.  |     | 0         |
| 15 | Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. International Journal of Cardiology, 2019, 281, 35-39.  | 1.7 | 52        |
| 16 | Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoprotein cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial. Scientific Reports, 2019, 9, 8537.  | 3.3 | 12        |
| 17 | Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial. Cardiovascular Diabetology, 2019, 18, 158.   | 6.8 | 12        |
| 18 | Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial. Cardiovascular Drugs and Therapy, 2018, 32, 73-80. | 2.6 | 20        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension. International Journal of Cardiology, 2018, 253, 161-166.   | 1.7 | 51        |
| 20 | The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1002051.   | 8.4 | 57        |
| 21 | Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. Cardiovascular Diabetology, 2016, 15, 87. | 6.8 | 28        |